ACTR-39. PAMIPARIB IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY (R/R) GLIOBLASTOMA (GBM); PHASE 1B/2 STUDY UPDATE

Abstract Pamiparib, an investigational, selective PARP1/2 inhibitor that has demonstrated potent PARP trapping and ability to cross the blood-brain barrier, showed synergistic cytotoxicity with TMZ preclinically. We report updated safety and antitumor effects from a phase 1b/2 study of pamiparib + R...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Neuro-oncology (Charlottesville, Va.) Va.), 2019-11, Vol.21 (Supplement_6), p.vi21-vi22
Hauptverfasser:	Piotrowski, Anna, Puduvalli, Vinay, Wen, Patrick, Campian, Jian, Colman, Howard, Pearlman, Michael, Butowski, Nicholas, Battiste, James, Glass, Jon, Cloughesy, Timothy, Schiff, David, van den Bent, Martin, Walbert, Tobias, Ahluwalia, Manmeet, Badruddoja, Michael, Kalra, Amandeep, Aregawi, Dawit, Weller, Michael, Ramakrishnan, Vanitha, Zhang, Kathy, Wood, Katie, Mellinghoff, Ingo, Shih, Kent
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Clinical Trials - Non-Immunologic
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!